

Estimating population average treatment effects from experiments with noncompliance

Kellie Ottoboni, Jason Poulos

April 24, 2015

Abstract

This is the abstract...

1 Introduction

Randomized control trials (RCTs) are the “gold standard” for estimating the causal effect of a treatment. However, external validity is often an issue when the individuals in an RCT are unrepresentative of the population of interest. For example, RCTs in which participants volunteer to sign up for health insurance coverage may exhibit a sample population that is in poorer health than the target population. External validity is particularly relevant to policy-makers who want to know how a sample average treatment effect (SATE) would generalize to the broader population. Hartman et al. propose a method of reweighting the responses of individuals in an RCT study according to the distribution of covariates in the target population in order to estimate the population average treatment effect on the treated (PATT). Under a series of assumptions, the PATT estimate is asymptotically unbiased (Hartman et al. [to appear]).

A prevalent issue in RCTs is non-compliance. One-way crossover from treatment to control occurs when individuals who are assigned to the treatment group refuse the treatment. This serves to dilute the effect of treatment assignment, and the resulting intention to treat estimate is biased towards 0. We propose to extend the method of Hartman et al. estimate the PATT in settings with RCT non-compliance. We make the same assumptions needed for the estimator proposed by Hartman et al. [to appear]; these include the stable unit treatment value assumption and strong ignorability. To ensure identifiability, we also assume monotonicity (no defiers) and exclusion restriction as in Angrist et al. [1996].

The estimator of PATT involves the expectation of the response of compliers in the RCT sample, conditional on their covariates, where the expectation is taken over the distribution of population covariates. To estimate the conditional expectation of responses in the RCT, we use an ensemble learning method to estimate the response surface. Then, we use the response model to estimate population members’ outcomes given their covariates, giving an

estimate of the PATT.

The paper proceeds as follows: Section 2 presents the proposed estimator, necessary assumptions for its identifiability, and an estimation procedure; Section 3 investigates the estimator’s performance in simulations; Section 4 uses the estimator to identify the effect of extending Medicare coverage to the low-income population in the U.S; Section 5 discusses the merits and flaws of the proposed estimator.

2 Estimator

We are interested in using the outcomes from an RCT to estimate the average treatment effect on the treated in some target population. Treatment in the population is not assigned at random, but rather depends on other variables, confounding the effect of treatment on the outcome of interest; RCTs are needed to isolate the effect of treatment. However, strict exclusion criteria for RCTs often result in a sample whose distribution of covariates differs substantially from the target population. Ideally, we would take the results of an RCT and reweight the sample such that the reweighted covariates match the those in the population. In practice, one rarely knows the true covariate distribution in the target population. Instead, we consider data from a non-randomized, observational study in which participants are representative of the target population. Our proposed estimator combines RCT and observational data to overcome these issues.

2.1 Assumptions

Let Y_{ist} be the potential outcome for individual i in group s , where $s = 0$ for the population and $s = 1$ for the randomized control trial, and t be the treatment assigned. Let T_i denote the treatment assigned and D_i denote treatment received. Let W_i be individual i ’s observable pretreatment covariates that are related to the sample selection mechanism for membership in the RCT, treatment assignment in the population, and complier status. Let C_i be an indicator for individual i ’s compliance to treatment. For a generic value, we drop the subscript i .

We assume that in the RCT, treatment is assigned at random. Then for individuals with $C_i = 1$, we observe $D_i = T_i$. In the population, we suppose that treatment is made available to individuals according to some rule based on their covariates; treatment assignment is not completely random. Individuals with $T_i = 0$ do not receive treatment, while those with $T_i = 1$ may decide whether or not to accept treatment. We only observe D , not T , in the population. Among the population controls, we can’t distinguish non-compliers (individuals with $T_i = 1$ and $D_i = 0$) from compliers (those with $T_i = 0$ and $D_i = 0$). Compliance is only observable for individuals assigned to treatment in the RCT.

We make the following assumptions:

Assumption 1. *Consistency under parallel studies: for all i and for $t = 0, 1$,*

$$Y_{i0t} = Y_{i1t}$$

Assumption 2. *Strong ignorability of sample assignment for treated:*

$$(Y_{01}, Y_{11}) \perp\!\!\!\perp S \mid (W, T = 1, C = 1), 0 < \mathbb{P}(S = 1 \mid W, T = 1, C = 1) < 1$$

This means that the potential outcomes for treatment are independent of sample assignment for individuals with the same covariates W and assignment to treatment.

Assumption 3. *Strong ignorability of sample assignment for controls:*

$$(Y_{00}, Y_{10}) \perp\!\!\!\perp S \mid (W, T = 1, C = 1), 0 < \mathbb{P}(S = 1 \mid W, T = 1, C = 1) < 1$$

This means that the potential outcomes for control are independent of sample assignment for individuals with the same covariates W and assignment to treatment.

Assumption 4. *Stable unit treatment value assumption (SUTVA):*

$$Y_{ist}^{L_i} = Y_{ist}^{L_j}, \forall i \neq j$$

where L_j is the treatment and sample assignment vector for unit j .

This means that the treatment assignment for all other individuals j does not affect the potential outcomes of individual i .

Assumption 5. *Conditional independence of compliance and assignment:*

$$C \perp\!\!\!\perp T = 1 \mid W, 0 < \mathbb{P}(C = 1 \mid W) < 1$$

This means that compliance is independent of sample and treatment assignment for all individuals with covariates W .

Assumption 6. *Monotonicity:*

$$T_i \geq D_i, \forall i$$

This assumption implies that there are no defiers and that crossover is only possible from treatment to control.

Assumption 7. *Exclusion restriction (ER): For non-compliers*

$$Y_{11} = Y_{10}$$

The treatment assignment affects the response only through the treatment received. In particular, the treatment effect may only be non-zero for compliers.

2.2 Population Average Treatment Effect on the Treated

The estimand of interest is

$$\tau_{\text{PATT}} = \mathbb{E}(Y_{01} - Y_{00} \mid S = 0, D = 1) \quad (1)$$

This is the average treatment effect on those in the population who receive treatment. It includes individuals who actually receive the treatment, but does not include those who are eligible for treatment and do not accept it (non-compliers).




Figure 1: Causal diagram indicating the conditional independence assumptions needed to estimate the PATT.

Theorem 1. *Under assumptions (1) - (7),*

$$\tau_{PATT} = \mathbb{E}_{01} [\mathbb{E}(Y_{11} \mid S = 1, D = 1, W)] - \mathbb{E}_{01} [\mathbb{E}(Y_{10} \mid S = 1, T = 0, C = 1, W)]$$

where $\mathbb{E}_{01} [\mathbb{E}(\cdot \mid \dots, W)]$ denotes the expectation with respect to the distribution of W in the treated individuals in the target population.

Proof. We separate the expectation into two terms and treat each individually.

$$\begin{aligned}
\mathbb{E}(Y_{01} \mid S = 0, D = 1) &= \mathbb{E}(Y_{11} \mid S = 0, D = 1) && \text{by (1)} \\
&= \mathbb{E}(Y_{11} \mid S = 0, T = 1, C = 1) && \text{by (6)} \\
&= \mathbb{E}_{01} [\mathbb{E}(Y_{11} \mid S = 1, T = 1, C = 1, W)] && \text{by (2)} \\
&= \mathbb{E}_{01} [\mathbb{E}(Y_{11} \mid S = 1, D = 1, W)]
\end{aligned}$$

$$\begin{aligned}
\mathbb{E}(Y_{00} \mid S = 0, D = 1) &= \mathbb{E}(Y_{10} \mid S = 0, D = 1) && \text{by (1)} \\
&= \mathbb{E}(Y_{10} \mid S = 0, T = 1, C = 1) && \text{by (6)} \\
&= \mathbb{E}_{01} [\mathbb{E}(Y_{10} \mid S = 1, T = 1, C = 1, W)] && \text{by (3)} \\
&= \mathbb{E}_{01} [\mathbb{E}(Y_{10} \mid S = 1, T = 0, C = 1, W)]
\end{aligned}$$

The last line follows because of the randomization carried out in the RCT. This ensures $Y_{10} \perp\!\!\!\perp T \mid (W, S = 1)$. \square

2.3 Estimation Procedure

Theorem 1 poses two challenges in practice. First, we must construct an estimate of the inner expectation over potential outcomes in the RCT. Here, we use random forests to estimate the

response curve for compliers, given their treatment assignment and covariates. We estimate the outer expectation by taking empirical means. Thus, the first term in the expression for τ_{PATT} is estimated by the weighted average of mean responses in the treatment group in the RCT. The second term is estimated by the weighted average of the mean control response for compliers assigned to control in the RCT. We compute these by evaluating the response curve for each treated individual in the population.

The second challenge is that we cannot observe which individuals are included in the estimation of the second term. We cannot tell who is a complier or non-complier in the control group, as they receive $D = 0$ in either case. We must estimate the second term by predicting who in the control group would be a complier, had they been assigned to treatment. The exact procedure for classification isn't important, as long as predictions are made as accurate as possible.

The procedure for estimating τ_{PATT} using theorem 1 as follows:

1. Using the group assigned to treatment in the RCT ($S = 1, T = 1$), train a model to predict complier status C using the covariates W .
2. Using the model from step 1, predict who in the RCT assigned to control *would have* complied to treatment had they been assigned to the treatment group.
3. For the group of observed compliers to treatment and predicted compliers in the control group, train a model to predict the response using as features the covariates W and the treatment T (assigned and observed are the same, for these individuals). This model gives $\mathbb{E}(Y_{1t} \mid S = 1, C = 1, T = t, W)$ for $t = 0, 1$.
4. For all individuals who received treatment in the population ($S = 0, D = 1$), estimate their potential outcomes Y_{10} and Y_{11} using the model from step 3. The mean counterfactual Y_{11} minus the mean counterfactual Y_{10} is the estimate of τ_{PATT} .

3 Simulations

We conduct a simulation study to compare the performance of the proposed estimator, Hartman et. al's estimator, and the instrumental variables estimate of the SATE, as estimators of τ_{PATT} . Our simulation is designed so that the effect of treatment is heterogeneous and depends on other covariates, and the design satisfies the conditional independence assumptions in Figure 1.

3.1 Simulation Design

RCT eligibility, complier status, and treatment assignment in the population depend on observed covariates. The observed covariates (W_1, W_2, W_3) are multivariate normal with mean $(0.5, 1, -1)$ and covariances $\text{Cov}(W_1, W_2) = 1$ and $\text{Cov}(W_1, W_3) = \text{Cov}(W_2, W_3) = 0.5$. The equation for selection into studies is

$$S = \mathbb{I}(e_2 + g_1 W_1 + g_2 W_2 + g_3 W_3 + R > 0)$$

where R is standard normal. e_2 controls the fraction of the population eligible for the RCT. We set g_1, g_2 , and g_3 to be 0.5, 0.25, and 0.75, respectively. Complier status is determined by

$$C = \mathbb{I}(e_3 + h_2 W_2 + h_3 W_3 + Q > 0)$$

where Q is standard normal. e_3 controls the fraction of compliers in the population. We set h_2 and h_3 to 0.5. For individuals in the population ($S = 0$), treatment is assigned by

$$T = \mathbb{I}(e_1 + f_1 W_1 + f_2 W_2 + V > 0)$$

Varying e_1 controls the fraction eligible for treatment in the population. V is standard normal. We set f_1 to 0.25 and f_2 to 0.75. For individuals in the RCT ($S = 1$), treatment assignment is a sample from a Bernoulli distribution. We set treatment received D according to T and C : $D = T$ if $C = 1$ and $D = 0$ if $C = 0$. Finally, the response Y is determined by

$$Y = a + bD + c_1 W_1 + c_2 W_2 + dU$$

We assume that the treatment effect b is heterogeneous depending on W_1 : $b = 1$ if $W_1 > 0.75$ and $b = -1$ if $W_1 \leq 0.75$. We set a, c_1 , and d to 1 and c_2 to 2. U is standard normal and $U, V, R, Q, (W_1, W_2, W_3)$ are mutually independent.

We generate a population of 30,000 individuals and randomly sample 5,000. Those among the 5,000 who are eligible for the RCT ($S = 1$) are selected. Similarly, we sample 5,000 individuals from the population and select those who are not eligible for the RCT ($S = 0$); these are a sample of the “target population”. We set each individual’s treatment received D according to their treatment assignment and complier status and observe their responses Y . In this design, the way that we’ve set S, T, D, C , and Y ensures that assumptions (1) - (7) hold.

In the assigned-treatment RCT group ($S = 1, T = 1$), we fit a logistic regression to compliance status using the covariates. With this model, we predict who in the control group ($S = 1, T = 0$) has $C = 1$, since this is unobservable. These individuals *would have* complied had they been assigned to the treatment group. For this group of observed compliers to treatment and predicted compliers from the control group of the RCT, we estimate the response curve using a random forest with features (W_1, W_2, W_3) and D . Then population local average treatment effect on the treated is estimated according to the estimation procedure outlined above.

3.2 Results

We vary each of the parameters e_1, e_2 , and e_3 along a grid by -2 to 2 in increments of 0.5 in order to generate different combinations of rates of compliance, treatment eligibility, and RCT eligibility in the population of 30,000. For each possible combination of the three parameters, we run the simulation 5 times and compute the mean squared error of our proposed estimator for τ_{PATT} that adjusts for non-compliance, the estimator from Hartman et al which is unadjusted for non-compliance, and the SATE using the instrumental variables

estimator from Angrist et al. [1996], given by the intention-to-treat estimate divided by the rate of compliance. All other parameters are held fixed. The unadjusted estimate is obtained by estimating the response curve on all individuals in the RCT and applying step 4 of our proposed estimation procedure to the non-randomized trial individuals.

Figure 2 shows the relationship between the percent of compliers in the whole population, the percentage of people in the whole population eligible to participate in the RCT, and the mean squared error of the PATT estimators. The pattern of performance is qualitatively similar for the adjusted and unadjusted estimators: both perform best when compliance is high and perform badly when compliance is low. Furthermore, for a fixed rate of compliance, the estimators tend to have lower mean squared error when either a very small or very large fraction of the total population is eligible to participate in the RCT.




Figure 2: Simulation mean squared error, transformed by $-\log$. Darker tiles correspond to lower mean squared error.

Figure 3 compares the mean squared error of the two PATT estimators and the SATE (as an estimator of PATT) at varying levels of compliance in the total population. When compliance is low, both PATT estimators have a large mean squared error and variance. The adjusted estimator has a large variance because the subset of the RCT who are considered compliers is relatively small, whereas the unadjusted estimator has large variance because of the large amount of crossover. For low levels of compliance, SATE actually tends to approximate PATT more closely; the variance due to small sample size contributes less to the mean squared error than the bias due to crossover in the other two estimators. On the other hand, when the compliance rate is high, both PATT estimators perform about equally well with mean squared error close to 0. Meanwhile, the median mean squared error for SATE stays relatively constant regardless of compliance rate. This shows that the instrumental variables estimate of SATE is able to adjust for the non-compliance, but is

unable to account for differences in pretreatment covariates between the RCT sample and target population.




Figure 3: Simulation mean squared error, according to compliance rates in the total population.

4 Empirical Example: Medicaid and Hospital Use

4.1 Data

We apply the proposed method to estimate the effect of extending Medicaid coverage on health care use. Medicaid is a federally-funded program, so understanding how the RCT estimates generalize to a broader population of individuals who will be covered by other Medicaid expansions is informative for public policy. In particular, we examine the population of nonelderly adults in the U.S. with household incomes at or below 138% of the FPL (about \$32,900 for a family of four in 2014) who may be eligible for Medicaid following the Affordable Care Act (ACA) expansion.

Oregon Health Insurance Experiment We draw RCT data from the Oregon Health Insurance Experiment (OHIE) Finkelstein et al. [2012], Taubman et al. [2014]. In 2008, approximately 90,000 uninsured low-income adults participated in a lottery to receive Medicaid benefits.¹ Treatment occurred at the household level: participants selected by the lottery won the opportunity for themselves and any household member to apply for Medicaid. Sample exclusions brought the sample size down to 74,922 individuals representing

¹Eligible participants include Oregon residents (US citizens or legal immigrants) aged 19 to 64 not otherwise eligible for public insurance, who have been without insurance for six months, and have income below the FPL and assets below \$2,000.

66,385 households. Within the sample, 29,834 participants were selected by the lottery; the remaining 45,008 participants served as controls in the experiment. Participants in selected households received benefits if they returned an enrollment application within 45 days of receipt. Among participants in selected households, about 60% mailed back applications and only 30% successfully enrolled.² We use the following pretreatment covariates as features in our prediction models: gender, age, race, ethnicity, health status, education, and household income.³

We use two health care use responses: emergency room (ER) and primary care visits in the past 12 months.⁴ These data originate from a mail survey that was administered to participants over July and August 2009 ($N = 23,741$ survey respondents) Finkelstein et al. [2012]. We use the same definition of insurance coverage as Finkelstein et al. [2012] to form our measure of compliance, which is a binary variable indicating whether the participant was enrolled in any Medicaid program (including the lotteried program) between the notification date and 30 September 2009. While Finkelstein et al.’s [2012] IVLS estimates of the effect of Medicaid assume one-way crossover, 14% of control participants were enrolled in Medicaid during the study period (compared to the 60% of treated participants who did not enroll).

Observational data We have data on the target population from a survey conducted by the Center for Disease Control: the National Health Interview Study (NHIS) for Health Statistics.

4.2 Assumptions

TO DO: DISCUSS HOW THE ASSUMPTIONS FOR ESTIMATING PATT ARE MET OR NOT MET BY THE DATA – JUST BRAINSTORMING FOR NOW

1. Consistency under parallel studies
2. Strong ignorability of sample assignment for treated
3. Strong ignorability of sample assignment for controls
4. SUTVA
5. Conditional independence of compliance and treatment assignment
6. Monotonicity: not satisfied! how did we address this?


²About half of the returned applications were deemed ineligible, primarily due to failure to demonstrate income below the FPL. Enrolled participants were required to recertify their eligibility status every six months.

³Since randomization is applied on the household level, we include the number of household members as a feature in all prediction models. Treatment is included as a feature in the response models.


⁴The variables that capture the total number of visits have been censored so that no individual value has fewer than ten observations.

7. Exclusion restriction: It would seem reasonable that whether or not someone actually has Medicaid, not their eligibility to enroll, would affect their hospital use. For generic health insurance one might argue that eligibility could be negatively correlated with hospital use, as people with pre-existing conditions may be less likely to be eligible yet go to the hospital more frequently. This should not be the case with a federally funded program such as Medicaid.

4.3 Results




(a) Any ER visit.




(b) Number of ER visits.

Figure 4: Comparison of estimators for treatment effect on ER use.



(a) Any primary care visit.



(b) Number of primary care visits.

Figure 5: Comparison of estimators for treatment effect on primary care use.

5 Discussion

The treatment effect of Medicaid applies to uninsured adults with income below the FPL who express interest in health insurance coverage. The sample population differs in several dimensions from the target population of individuals who will be covered by other Medicaid expansions, such as the ACA expansion to cover all adults up to 138% of the FPL. For instance, the RCT participants are disproportionately white urban-dwellers Taubman et al. [2014]. The RCT participants volunteered for the study and therefore may be in poorer health compared to the population.

Simulations shed light on the conditions under which the proposed estimator should work well. When the rate of crossover from treatment to control is low, the proposed estimator performs better than the estimator which doesn't adjust for non-compliance. Here, the unadjusted estimator gives the intention-to-treat effect, which tends to underestimate the average treatment effect on compliers. Of course, the simulation results depend on the particular way we parameterized the compliance, selection, treatment assignment, and response schedules. In particular, the strength of correlation between the covariates and compliance governs how well the estimator will perform, since step one of the estimation procedure is to predict who *would be* a complier in the RCT control group, had they been assigned to treatment. If it is difficult to predict compliance using the observed covariates, then the estimator will perform badly because of noise introduced by incorrectly treating non-compliers as compliers. Further research should be done into ways to test how well compliance can be predicted.

In the OHIE trial, only about 30% of those selected to receive Medicaid benefits actually enrolled successfully, and successful enrollment depended in part on income levels. The proposed estimator that adjusts for non-compliance seems to perform better than the unadjusted estimator when compliance is low and can be predicted by observed covariates (Figure 3). Our random forest for predicting compliance based on observed covariates has about 61.5% accuracy on the training set of individuals in OHIE assigned to the treatment group. While we don't know well how the model predicts for the control group, its performance on the training set suggests that compliance is not purely random, but depends on observed covariates. This gives evidence in favor of using the proposed estimator. Future work should be done to construct a better model to predict compliance, both in the treated group used for training and the controls in the RCT.

TO DO: UPDATE TO REFLECT WHAT WE EXPECTED + WHAT WE ACTUALLY SAW

The proposed method allows us to decompose both SATE and PATT estimates by subgroup according to covariates common to both RCT and observational datasets (e.g, demographic variables, pre-existing conditions, and insurance coverage). Since the RCT participants are predominately white and volunteered for the study, we expect to find substantial differences between sample and population estimates in terms of ethnicity and pre-existing condition subgroups. Overall, we expect the PATT estimate to be lower than the SATE estimate due to the adverse selection problem in the RCT.

References

- Joshua D. Angrist, Guido W. Imbens, and Donald B. Rubin. Identification of causal effects using instrumental variables. *Journal of the American Statistical Association*, 91(434): 444–455, June 1996.
- Amy Finkelstein, Sarah Taubman, Bill Wright, Mira Bernstein, Jonathan Gruber, Joseph P Newhouse, Heidi Allen, Katherine Baicker, Oregon Health Study Group, et al. The oregon health insurance experiment: Evidence from the first year. *The quarterly journal of economics*, 127(3):1057, 2012.
- Centers for Disease Control and Prevention. Behavioral risk factor surveillance system. <http://www.cdc.gov/brfss/index.html>. April 2015.
- National Center for Health Statistics. National health interview survey. <http://www.cdc.gov/nchs/nhis.htm>. April 2015.
- Erin Hartman, Richard Grieve, Roland Ramsahai, and Jasjeet S. Sekhon. From sate to patt: Combining experimental with observational studies to estimate population treatment effects. *Journal of the Royal Statistical Society, Series A*, to appear.
- Sarah Taubman, Heidi Allen, Bill Wright, Katherine Baicker, Amy Finkelstein, and the Oregon Health Study Group. Medicaid increases emergency department use: Evidence from oregon’s health insurance experiment. *Science*, 343(6168):263–268, January 2014.

Appendix